To Whom It May Concern

April 5, 2019

NanoCarrier Co. Ltd.
Ichiro Nakatomi, President & CEO
(Code No. 4571 TSE Mothers)

# Patient Enrollment Completion of NC-6004 Phase III Study for Pancreatic Cancer

NanoCarrier and our Taiwanese licensing partner, Orient Europharma, have been conducting an NC-6004 Phase III clinical study in patients with pancreatic cancer as a Japan/Asia joint development. We are announcing that patient enrollment of this study completed both in Japan and Asia, as the number of enrolled patients was sufficient to perform statistical analysis.

In this study, NC-6004 administration is ongoing in some patients. The topline data is expected to be available in the first half of the fiscal year 2020, following the observation period.

Please note that this will have no impact on the business results for the fiscal year ending March 2019.

Contact: Tetsuhito Matsuyama
Director, CSFO and Head of CEO's Office
Phone: +81-3-3241-0553